ESR1 and neoplasm: High-dose TOR has been reported to compete with estrogen at the ligand-binding site of the ER, to suppress insulin-like growth factor-1-dependent growth[6] and to have non-ER-dependent anti-tumor effects such as suppression of angiogenesis[7].